# Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)

> **NCT05321875** · PHASE3 · RECRUITING · sponsor: **Cristina Avendaño Solá** · enrollment: 320 (estimated)

## Conditions studied

- Cardiomyopathy, Dilated

## Interventions

- **DRUG:** Candesartan

## Key facts

- **NCT ID:** NCT05321875
- **Lead sponsor:** Cristina Avendaño Solá
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-02
- **Primary completion:** 2026-06-02
- **Final completion:** 2026-06-02
- **Target enrollment:** 320 (ESTIMATED)
- **Last updated:** 2024-11-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05321875

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05321875, "Early Treatment With Candesartan vs Placebo in Genetic Carriers of Dilated Cardiomyopathy (EARLY-GENE Trial)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT05321875. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*